Novel Applications of JAK Inhibitors in Water Quality, Pipeline Corrosion, Plant Health, Medical Implants, and Agriculture
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of JAK inhibitors to address unmet needs in various industries, including water quality monitoring, pipeline corrosion prevention, plant health management, medical implant biofilm detection, and agricultural crop yield improvement.
Background and Problem Solved
The original patent disclosed methods and compositions for treating diseases of the gastrointestinal tract with JAK inhibitors. However, the limitations of this technology lie in its narrow application scope. The new inventive concept addresses this limitation by exploring novel applications of JAK inhibitors in unrelated fields, thereby expanding the technology's potential impact and value.
Detailed Description of the Inventive Concept
The inventive concept encompasses five distinct applications of JAK inhibitors: 1) a system for monitoring water quality, where an ingestible device releases a JAK inhibitor to treat aquatic life affected by pollutants; 2) a method for preventing corrosion in pipelines by administering a JAK inhibitor via an ingestible device; 3) a composition for treating fungal infections in plants, combining a JAK inhibitor with a plant growth promoter; 4) a device for detecting and treating biofilm formation on medical implants, using an ingestible device that releases a JAK inhibitor and a sensor that detects biofilm formation; and 5) a system for improving crop yields, comprising a network of soil sensors and an ingestible device that releases a JAK inhibitor to treat soil microorganisms.
Novelty and Inventive Step
The new inventive concept introduces novel and non-obvious applications of JAK inhibitors, departing from the original patent's gastrointestinal tract focus. The inventive step lies in recognizing the potential of JAK inhibitors to address diverse problems across various industries, thereby expanding the technology's scope and value.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include different types of sensors, ingestible devices, or JAK inhibitors. Variations could involve adapting the technology for use in other industries, such as environmental remediation or cosmetics.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various markets, including water quality monitoring, pipeline maintenance, agricultural technology, medical devices, and plant health management. The market size for these applications is substantial, with opportunities for partnerships, licensing, and new product development.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/0009 |
| A | A61 | A61K9/0004 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K31/519 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical drug delivery systems, biotechnology, and medical device technologies with a focus on targeted drug administration and biological inhibition mechanisms
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical sciences, bioengineering, or chemical engineering, possessing expertise in drug delivery mechanisms, biological inhibition techniques, and interdisciplinary technology applications
Obviousness Rationale
A PHOSITA would recognize that JAK inhibitors represent a versatile molecular mechanism with broad potential applications beyond gastrointestinal treatments. The source patent's fundamental disclosure of targeted JAK inhibitor delivery provides a clear technological foundation for exploring alternative industrial and environmental applications. The PTD's variations represent predictable extensions of known JAK inhibition principles, applying established drug delivery and sensor technologies to novel problem domains.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,669 |
|---|---|
| Title | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices |
| Assignee(s) | Biora Therapeutics, Inc. |